Tunisia Pharmaceutical Market size was valued at US$ 1.5 Bn in 2020 and the total revenue is expected to grow at 12.9 % through 2021 to 2027, reaching nearly US$ 3.4 Bn.
Tunisia Pharmaceutical Market Overview:Tunisia is the smallest nation in North Africa, bordered to the west by Algeria, to the southeast by Libya, and the north and east by the Mediterranean Sea. Tunisia is one of the few countries in Africa with sophisticated management and advanced technologies pharmaceutical sector, both in terms of product quality and safety. The generic drug local production is approximately 49% and importations are around 51%. Major countries of Tunisia are Tunis (Capital), Sfax, Sousse, Ettadhamen, Kairouan, Gabès. Tunis has approx. 39 pharmaceutical companies in the region. Tunisia also encourages the local production of generic medicines. To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2026. 2019 is considered a base year however 2021's numbers are on the real output of the companies in the market. Special attention is given to 2021 and the effect of lockdown on the demand and supply, and the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and specific strategic analysis of those companies is done in the report.
Tunisia Pharmaceutical Market Dynamics:The availability of different established and integrated facilities that support R&D and pharmaceutical manufacturers in the country drives the market. The healthcare system of Tunisia is one of the most sophisticated in the Middle East and North Africa. Tunisia is an appealing market for pharmaceutical businesses, with a huge consumer base, growing healthcare expenditures, and expanding disposable incomes. Tunisia's pharmaceutical sector is mostly based on joint ventures with multinational companies. These multinational corporations make considerable investments in local players to improve pharmaceutical medication products R&D. Sanofi, for example, has invested heavily in local businesses. As a consequence, the aforementioned factors are expected to have a favorable influence on market growth. Additionally, the pharmaceutical sector in Tunisia has benefited from the presence of R&D facilities that promote the establishment of research clusters and scientific advancement. Tunisia's pharmaceutical sector aspires to increase exports, notably to European and West African markets, in order to capitalize on its well-developed manufacturing base and obtain easy access to Europe and Africa. SAIPH (Société Arabe des Industries Pharmaceutiques) has become one of the attractive investments to enhance export manufacturing capabilities. SAIPH has declared shipments to adjacent North African countries notably Algeria, Mauritania, and Libya, as well as West African nations, in recent years. The pharmaceutical sector in Tunisia has grown significantly in the last two decades, as per the government. As of August 2019, this industry had received USD 105 million in investments. As a consequence of an enhanced investment in the pharmaceutical industry, operational players interested in growing their company in the region will have attractive prospects. Pharmaceutical producers in the nation are also expanding their export reach to European and West African countries as a result of export growth. As a result, the firms are investing heavily to extend their industrial capacity. In 2020, Pfizer, Inc. was the leading drug company in Tunisia, followed by Sanofi-Aventis Tunisia. Adwa is another well-known pharmaceutical company in Tunisia, contributing to more than 10% of the country's medication production. Les Laboratoires UNIMED, Teriak, MEDIS, SIPHAT, OPALIA PHARMA, Taha Pharma, and Cytopharma are the next in line.
Tunisia Pharmaceutical Market Segment Analysis:
The tablet formulation segment is anticipated to adhere to the growth of the Tunisia Pharmaceutical Market.In 2020, the tablet formulation category held the largest market share, contributing to 24.5 % revenue. The most popular oral solid dosage form for medication administration is tablets, which leads to their enormous production and sales. The advantages of this type of formulation over capsules include temperature resistance, cost-effectiveness, ease of handling and packing, and high production efficiency, mask the taste, ease to swallow. Tablets are the most convenient to make for a wide range of products, namely antidiabetics, anti-inflammatories, antacids, vitamins, and antiallergics. The capsule formulation segment, on the other hand, is expected to develop strongly shortly. From 2020 to 2027, the category is likely to grow at the fastest rate of 14%. The rise of the sector may be linked to its growing application in gastroenterology. The gastro-resistant capsules are among the most popular forms of modified drug release systems that offer numerous benefits such as fewer side effects and drug absorption. The objective of the report is to present a comprehensive analysis of the Tunisia Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Tunisia Pharmaceutical Market dynamics, structure by analyzing the market segments and project the Tunisia Pharmaceutical Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Tunisia Pharmaceutical Market make the report investor’s guide.
Tunisia Pharmaceutical Market Scope: Inquire before buying
Tunisia Pharmaceutical Market Key Players• Adwya • Sanofi (Sanofi-Aventis Tunisia) • Teriak • Opalia pharma • Les Laboratoires UNIMED • Medis • Taha Pharma • Cytopharma • Novartis • Abbvie • GlaxoSmithKline • Roche • Unimed • IPHAT. • Pierre Fabre • Bayer Schering • Leiras • Orion Farmos • Orion Pharma • Pfizer • Santen.
FAQs:1. What is the Tunisia Pharmaceutical Market value in 2020? Ans: The Tunisia Pharmaceutical Market value in 2020 was estimated as 1.5 Billion USD. 2. What is the Tunisia Pharmaceutical Market growth? Ans: The Tunisia Pharmaceutical Market is anticipated to grow with a CAGR of 12.9% in the forecast period and is likely to reach USD 3.4 Billion by the end of 2027. 3. Which Formulation segment is expected to dominate the Tunisia Pharmaceutical Market during the forecast period? Ans: The tablet formulation segment dominated the Tunisia pharmaceutical market in 2020 and accounted for the largest revenue share of 24.5%. 4. Who are the key players in the Tunisia pharmaceutical market? Ans: Some key players operating in the Tunisia pharmaceutical market include Les Laboratoires UNIMED, Teriak, MEDIS, SIPHAT, OPALIA PHARMA, Taha Pharma, and Cytopharma. 5. What is the key driving factor for the growth of the Tunisia Pharmaceutical Market? Ans: Tunisia's pharmaceutical market is driven by the presence of various developed and integrated facilities that promote R&D, production of pharmaceuticals in the country. Tunisia’s healthcare system is one of the more advanced health systems in the Middle East and North Africa.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 188.8.131.52. Secondary data 184.108.40.206. Secondary Technology 2.3.2. Primary Research 220.127.116.11. Data from Primary Technology 18.104.22.168. Breakdown of Primary Technology 3. Executive Summary: Tunisia Pharmaceutical Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2020 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Tunisia Pharmaceutical Market 3.4. Geographical Snapshot of the Tunisia Pharmaceutical Market, By Manufacturer share 4. Tunisia Pharmaceutical Market Overview, 2021-2027 4.1. Market Dynamics 4.1.1. Drivers 22.214.171.124. Global 126.96.36.199. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 188.8.131.52. Global 184.108.40.206. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 220.127.116.11. Global 18.104.22.168. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 22.214.171.124. Global 126.96.36.199. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 188.8.131.52. Threat of New Entrants 184.108.40.206. Bargaining Power of Buyers/Consumers 220.127.116.11. Bargaining Power of Suppliers 18.104.22.168. Threat of Substitute Grades 22.214.171.124. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Tunisia Pharmaceutical Market 5. Supply Side and Demand Side Indicators 6. Tunisia Pharmaceutical Market Analysis and Forecast, 2021-2027 6.1. Tunisia Pharmaceutical Market Size & Y-o-Y Growth Analysis. 7. Tunisia Pharmaceutical Market Analysis and Forecasts, 2021-2027 7.1. Market Size (Value) Estimates & Forecast By Formulation, 2021-2027 7.1.1. Tablets 7.1.2. Capsules 7.1.3. Injectables 126.96.36.199. BFS-mode 188.8.131.52. Non-BFS-mode 7.1.4. Sprays 184.108.40.206. BFS-mode 220.127.116.11. Non-BFS-mode 7.1.5. Suspensions 18.104.22.168. BFS-mode 22.214.171.124. Non-BFS-mode 7.1.6. Powders 7.1.7. Other Formulations 126.96.36.199. BFS-mode 188.8.131.52. Non-BFS-mode 8. Tunisia Pharmaceutical Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2027 8.1.1. Tunisia 9. Competitive Landscape 9.1. Geographic Footprint of Major Players in the Tunisia Pharmaceutical Market 9.2. Competition Matrix 9.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 9.2.2. New Grade Launches and Grade Enhancements 9.2.3. Market Consolidation 184.108.40.206. M&A by Regions, Investment, and Verticals 220.127.116.11. M&A, Forward Integration and Backward Integration 18.104.22.168. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 9.3. Company Profile: Key Players 9.3.1. Adwya 22.214.171.124. Company Overview 126.96.36.199. Financial Overview 188.8.131.52. Geographic Footprint 184.108.40.206. Grade Portfolio 220.127.116.11. Business Strategy 18.104.22.168. Recent Developments 9.3.2. Adwya 9.3.3. Sanofi (Sanofi-Aventis Tunisia) 9.3.4. Teriak 9.3.5. Opalia pharma 9.3.6. Les Laboratoires UNIMED 9.3.7. Medis 9.3.8. Taha Pharma 9.3.9. Cytopharma 9.3.10. Novartis 9.3.11. Abbvie 9.3.12. GlaxoSmithKline 9.3.13. Roche 9.3.14. Unimed 9.3.15. IPHAT. 9.3.16. Pierre Fabre 9.3.17. Bayer Schering 9.3.18. Leiras 9.3.19. Orion Farmos 9.3.20. Orion Pharma 9.3.21. Pfizer and Santen. Primary Key Insights